Australian clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has received approval from Human Research Ethics Committee (HREC) to initiate a Phase I clinical trial of PD1-Vaxx in Australia.
A comprehensive cancer hospital situated in Sydney, Chris O’Brien Lifehouse is the first one to attain ethics approval. Further clinical sites will be opened in Australia as well as the US, following an FDA (Food and Drug Administration) investigational new drug (IND).
Imugene notified that the ethics approval process represents the first independent review of PD1-Vaxx pre-clinical efficacy and safety data.
As at 12:51 PM AEST, IMU traded at $0.035, with a rise of ~3%.